An Open-label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-mutated Advanced Solid Tumours

Trial Profile

An Open-label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-mutated Advanced Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs RG 7256 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 13 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
    • 01 Sep 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top